

Joshua D Rosenblat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4680745/joshua-d-rosenblat-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

170
papers

4,183
citations

40
h-index

59
g-index

182
ext. papers

6,360
ext. citations

6.2
avg. IF

6.14
L-index

#	Paper	IF	Citations
170	Immune Response to Vaccination in Adults with Mental Disorders: A Systematic Review.. <i>Journal of Affective Disorders</i> , 2022 , 304, 66-66	6.6	0
169	Olanzapine and samidorphan combination treatment: A systematic review.. <i>Journal of Affective Disorders</i> , 2022 , 301, 99-106	6.6	0
168	Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis. <i>Journal of Affective Disorders</i> , 2022 , 296, 514-521	6.6	3
167	The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.. <i>Psychopharmacology</i> , 2022 , 1	4.7	1
166	Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research.. <i>Infectious Diseases</i> , 2022 , 1-11	3.1	2
165	The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-12	4.1	2
164	Sex differences in ketamine@ therapeutic effects for mood disorders: A systematic review.. <i>Psychiatry Research</i> , 2022 , 312, 114579	9.9	0
163	Pharmacogenomics of ketamine: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 145, 27-34	5.2	3
162	Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. <i>CNS Drugs</i> , 2021 , 36, 17	6.7	5
161	Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence. <i>Psychiatry Research</i> , 2021 , 307, 114321	9.9	0
160	Fatigue and Cognitive Impairment in Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis.. <i>Brain, Behavior, and Immunity</i> , 2021 ,	16.6	60
159	Prevalence of Type 2 Diabetes Mellitus, Impaired Fasting Glucose, General Obesity, and Abdominal Obesity in Patients with Bipolar Disorder: A Systematic Review and Meta-analysis.. <i>Journal of Affective Disorders</i> , 2021 , 300, 449-449	6.6	3
158	Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine@ mechanisms associated with antidepressant and psychotomimetic effects. <i>Psychiatry Research</i> , 2021 , 306, 114231	9.9	1
157	Peripheral inflammatory biomarkers define biotypes of bipolar depression. <i>Molecular Psychiatry</i> , 2021 , 26, 3395-3406	15.1	4
156	A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. <i>Journal of Affective Disorders</i> , 2021 , 282, 160-164	6.6	4
155	Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9). <i>Journal of Psychiatric Research</i> , 2021 , 135, 311-317	5.2	6
154	Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021 , 282, 448-453	6.6	2

153	Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application. <i>Psychiatry Research</i> , 2021 , 298, 113800	9.9	3
152	Strategies to Prolong Ketamine® Efficacy in Adults with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021 , 38, 2795-2820	4.1	6
151	Barriers, benefits and interventions for improving the delivery of telemental health services during the coronavirus disease 2019 pandemic: a systematic review. <i>Current Opinion in Psychiatry</i> , 2021 , 34, 434-443	4.9	5
150	Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 137, 426-436	5.2	12
149	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021 , 178, 383-399	11.9	67
148	The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 137, 232-241	5.2	8
147	A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat. <i>Journal of Affective Disorders</i> , 2021 , 286, 360-369	6.6	9
146	The impact of overweight/obesity on monetary reward processing: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 137, 456-464	5.2	3
145	Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. <i>Journal of Affective Disorders</i> , 2021 , 288, 210-216	6.6	1
144	Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. <i>Journal of Sleep Research</i> , 2021 , e13400	5.8	2
143	The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence. <i>Psychiatry Research</i> , 2021 , 300, 113860	9.9	0
142	Association Between Mood Disorders and Risk of COVID-19 Infection, Hospitalization, and Death: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2021 , 78, 1079-1091	14.5	35
141	Registered clinical studies investigating psychedelic drugs for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2021 , 139, 71-81	5.2	12
140	Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries. <i>Journal of Affective Disorders</i> , 2021 , 290, 364-377	6.6	53
139	Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 104, 110032	5.5	4
138	Is ketamine a litmus test for capacity in assisted dying with depression?. <i>Psycho-Oncology</i> , 2021 , 30, 417-420	5.9	0
137	Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychiatric Research</i> , 2021 , 136, 444-451	5.2	1
136	Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 105, 110126	5.5	7

135	The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Psychopharmacology</i> , 2021 , 35, 128-136	4.6	2
134	The influence of prescriber and patient gender on the prescription of benzodiazepines: evidence for stereotypes and biases?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021 , 56, 1083-1089	4.5	4
133	Exploring brain insulin resistance in adults with bipolar depression using extracellular vesicles of neuronal origin. <i>Journal of Psychiatric Research</i> , 2021 , 133, 82-92	5.2	8
132	The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2021 , 134, 57-68	5.2	21
131	The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 120, 78-85	9	13
130	Effects of infliximab on brain neurochemistry of adults with bipolar depression. <i>Journal of Affective Disorders</i> , 2021 , 281, 61-66	6.6	3
129	The Prevalence of Suicidal Behaviour in Fibromyalgia Patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 108, 110078	5.5	3
128	Novel therapeutic drug targets for bipolar disorder 2021 , 393-404		
127	The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset. <i>CNS Spectrums</i> , 2021 , 1-5	1.8	2
126	Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. <i>Psychopharmacology</i> , 2021 , 238, 917-926	4.7	6
125	Immunity as a Common Risk Pathway for Psychiatric and Medical Comorbidity 2021 , 41-50		
124	Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 63-74	3.7	4
123	Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. <i>CNS Spectrums</i> , 2021 , 1-9	1.8	2
122	Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. <i>CNS Drugs</i> , 2021 , 35, 925-934	6.7	5
121	The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE). <i>Psychiatry Research</i> , 2021 , 302, 113993	9.9	5
120	Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?. <i>Journal of Affective Disorders</i> , 2021 , 292, 714-719	6.6	4
119	Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic. <i>Psychiatry Research</i> , 2021 , 303, 114086	9.9	0
118	Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 899-913	6.5	6

117	Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction. <i>Journal of the Royal Society of Medicine</i> , 2021 , 114, 473-479	2.3	12
116	Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. <i>Journal of Psychiatric Research</i> , 2021 , 144, 129-137	5.2	25
115	Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. <i>Journal of Affective Disorders</i> , 2021 , 293, 285-294	6.6	5
114	Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot study. <i>Journal of Affective Disorders</i> , 2021 , 293, 73-77	6.6	2
113	The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. <i>Journal of Affective Disorders</i> , 2021 , 294, 592-596	6.6	1
112	Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence. <i>Journal of Psychiatric Research</i> , 2021 , 143, 209-214	5.2	0
111	Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2021 , 131, 192-210	9	2
110	The neurodevelopmental basis of bipolar disorder: Mechanisms and implications 2021 , 11-21		
109	Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials. <i>CNS Spectrums</i> , 2021 , 1-22	1.8	3
108	The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. <i>Bipolar Disorders</i> , 2020 , 22, 831-840	3.8	18
107	The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020 , 274, 903-910	6.6	37
106	The utility of smartphone-based, ecological momentary assessment for depressive symptoms. <i>Journal of Affective Disorders</i> , 2020 , 274, 602-609	6.6	15
105	Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1031-1040	4.1	9
104	The Mental Health Effects of COVID-19 on Health Care Providers in China. <i>American Journal of Psychiatry</i> , 2020 , 177, 635-636	11.9	48
103	Synergistic effect of social media use and psychological distress on depression in China during the COVID-19 epidemic. <i>Psychiatry and Clinical Neurosciences</i> , 2020 , 74, 552-554	6.2	11
102	The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change. <i>Frontiers in Psychiatry</i> , 2020 , 11, 546	5	8
101	Trace elements differences in the depression sensitive and resilient rat models. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 529, 204-209	3.4	7
100	Leptin mediates improvements in cognitive function following treatment with infliximab in adults with bipolar depression. <i>Psychoneuroendocrinology</i> , 2020 , 120, 104779	5	6

99	Pharmacological Treatment of Major Depressive Disorder 2020 , 103-119		1
98	Neurodevelopmental pathways in bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2020 , 112, 213-226	9	22
97	Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. <i>Psychiatry Research</i> , 2020 , 288, 112967	9.9	0
96	The Association Between Adverse Childhood Experiences and Inflammation in Patients with Major Depressive Disorder: A Systematic Review. <i>Journal of Affective Disorders</i> , 2020 , 272, 1-7	6.6	10
95	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020 , 98, 683-697H	8.2	15
94	Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. <i>Brain, Behavior, and Immunity</i> , 2020 , 88, 631-639	16.6	20
93	Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder. <i>Psychiatry Research</i> , 2020 , 284, 112767	9.9	1
92	Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. <i>CNS Spectrums</i> , 2020 , 1-9	1.8	2
91	Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. <i>CNS Spectrums</i> , 2020 , 1-7	1.8	1
90	Leptin, obesity, and response to ketamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 98, 109773	5.5	4
89	Depression in the medically ill. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020 , 54, 346-366	2.6	13
88	The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis. <i>Psychiatry Research</i> , 2020 , 294, 113514	9.9	28
87	Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence. <i>Journal of Affective Disorders</i> , 2020 , 276, 570-575	6.6	11
86	Bipolar disorders. <i>Lancet, The</i> , 2020 , 396, 1841-1856	40	124
85	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020 , 276, 576-584	6.6	44
84	The emerging role of psilocybin and MDMA in the treatment of mental illness. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 1263-1273	4.3	10
83	Registered clinical trials investigating ketamine for psychiatric disorders. <i>Journal of Psychiatric Research</i> , 2020 , 127, 1-12	5.2	14
82	Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. <i>Cells</i> , 2020 , 9,	7.9	14

81	Impact of SARS-CoV-2 Infection on Cognitive Function: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2020 , 11, 621773	5	29
80	Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. <i>Journal of Psychopharmacology</i> , 2019 , 33, 1388-1394	4.6	9
79	Potential differences in antidepressant effects of oral ketamine liquid suspension versus compounded capsules. <i>British Journal of Psychiatry</i> , 2019 , 215, 434	5.4	2
78	Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2019 , 76, 783-790	14.5	83
77	Stress, epigenetics and depression: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 102, 139-152	9	114
76	Consumer Warning for Genetic Tests Claiming to Predict Response to Medications: Implications for Psychiatry. <i>American Journal of Psychiatry</i> , 2019 , 176, 412-413	11.9	1
75	Parental characteristics and the risk of schizophrenia in a Chinese population: a case-control study. <i>Nordic Journal of Psychiatry</i> , 2019 , 73, 90-95	2.3	4
74	Letter to the Editor: Clinical versus statistical significance of pharmacogenomic-guided antidepressant therapy: What's really being measured and marketed?. <i>Journal of Psychiatric Research</i> , 2019 , 114, 208-209	5.2	6
73	The neural systems of emotion regulation and abnormalities in major depressive disorder. <i>Behavioural Brain Research</i> , 2019 , 367, 181-188	3.4	30
72	The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 387-404	5.5	35
71	Management Commentary 2019 , 263-267		
70	Oral Ketamine for Depression: A Systematic Review. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	45
69	Targeting the immune system in the treatment of bipolar disorder. <i>Psychopharmacology</i> , 2019 , 236, 2909-2921	4.7	27
68	Trial of SAGE-217 in Patients with Major Depressive Disorder. <i>New England Journal of Medicine</i> , 2019 , 381, 2178-2179	59.2	2
67	Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design. <i>Psychiatry and Clinical Neurosciences</i> , 2019 , 73, 100-108	6.2	13
66	Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 1-7	5.5	15
65	The long-term effect of bariatric surgery on depression and anxiety. <i>Journal of Affective Disorders</i> , 2019 , 246, 886-894	6.6	51
64	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019 , 24, 154-162	1.8	9

63	Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 109-117	5.5	44
62	Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2019 , 243, 116-120	6.6	32
61	Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 475-482	5.5	10
60	Targeting cytokines in reduction of depressive symptoms: A comprehensive review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 83, 86-91	5.5	42
59	Are Antidepressants Harmful in the "General Population"? <i>Psychotherapy and Psychosomatics</i> , 2018 , 87, 179	9.4	1
58	Depressive disorders: Processes leading to neurogeneration and potential novel treatments. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 80, 189-204	5.5	29
57	Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. <i>Journal of Affective Disorders</i> , 2018 , 227, 219-225	6.6	92
56	Drug-drug interactions as a result of co-administering Δ^9 THC and CBD with other psychotropic agents. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 51-54	4.1	49
55	Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 94, 11-16	9	53
54	Predicting antidepressant response using early changes in cognition: A systematic review. <i>Behavioural Brain Research</i> , 2018 , 353, 154-160	3.4	16
53	Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	47
52	Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?. <i>Brain, Behavior, and Immunity</i> , 2018 , 73, 115-124	16.6	53
51	Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review. <i>Journal of Affective Disorders</i> , 2018 , 241, 519-532	6.6	95
50	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2018 , 241, 484-491	6.6	59
49	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018 , 238, 228-232	6.6	6
48	Therapeutic potential of JAK/STAT pathway modulation in mood disorders. <i>Reviews in the Neurosciences</i> , 2018 , 30, 1-7	4.7	19
47	Factors That Impact Treatment Decisions: Results From an Online Survey of Individuals With Bipolar and Unipolar Depression. <i>primary care companion for CNS disorders, The</i> , 2018 , 20,	1.2	6
46	Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2018 , 227, 406-415	6.6	66

45	Letter to the editor: Inadequate evidence to support improved patient outcomes with combinatorial pharmacogenomics. <i>Journal of Psychiatric Research</i> , 2018 , 107, 136-137	5.2	1
44	Revising , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018 , 52, 1173-1182	2.6	12
43	Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. <i>Neuroscience Letters</i> , 2018 , 686, 10-16	3.3	41
42	Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. <i>Amino Acids</i> , 2018 , 50, 1013-1023	3.5	26
41	Evidence supporting a mechanistic role of sirtuins in mood and metabolic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 86, 95-101	5.5	24
40	Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2467-2471	6.7	50
39	Inflammation in Bipolar Disorder 2018 , 445-454		3
38	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 38-50	1.4	23
37	Frequency of use and perceived helpfulness of wellness strategies for bipolar and unipolar depression. <i>Annals of Clinical Psychiatry</i> , 2018 , 30, 296-304	1.4	6
36	Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 410-423	3.8	24
35	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). <i>Scandinavian Journal of Pain</i> , 2017 , 15, 62-67	1.9	8
34	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017 , 22, 203-219	1.8	72
33	Cannabidiol in medical marijuana: Research vistas and potential opportunities. <i>Pharmacological Research</i> , 2017 , 121, 213-218	10.2	73
32	The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 412-418	1.7	42
31	Treatment of mixed features in bipolar disorder. <i>CNS Spectrums</i> , 2017 , 22, 141-146	1.8	10
30	Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems. <i>Journal of Affective Disorders</i> , 2017 , 211, 99-106	6.6	55
29	Dementia with Lewy bodies presenting as psychotic depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017 , 51, 1160-1161	2.6	2
28	Pharmacological Approaches to Minimizing Cardiometabolic Side Effects of Mood Stabilizing Medications. <i>Current Treatment Options in Psychiatry</i> , 2017 , 4, 319-332	3.1	5

27	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017 , 222, 14-20	6.6	20
26	Treatment recommendations for DSM-5-defined mixed features. <i>CNS Spectrums</i> , 2017 , 22, 147-154	1.8	12
25	Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications. <i>Brain Sciences</i> , 2017 , 7,	3.4	102
24	Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD. <i>Current Pharmaceutical Design</i> , 2017 , 23, 2065-2072	3.3	19
23	Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 720-729	4.6	92
22	A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 50-6	1.7	46
21	Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2016 , 18, 89-101	3.8	125
20	Mapping inflammation onto mood: Inflammatory mediators of anhedonia. <i>Neuroscience and Biobehavioral Reviews</i> , 2016 , 64, 148-66	9	79
19	Bipolar Disorder and Inflammation. <i>Psychiatric Clinics of North America</i> , 2016 , 39, 125-37	3.1	83
18	Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016 , 14, 1-16	3.4	86
17	Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms. <i>Current Molecular Medicine</i> , 2016 , 16, 165-78	2.5	17
16	Pharmacologic implications of inflammatory comorbidity in bipolar disorder. <i>Current Opinion in Pharmacology</i> , 2016 , 29, 63-9	5.1	16
15	Assessing and measuring cognitive function in major depressive disorder. <i>Evidence-Based Mental Health</i> , 2016 , 19, 106-109	11.1	18
14	Deconstructing Diabetes and Depression: Clinical Context, Treatment Strategies, and New Directions. <i>Focus (American Psychiatric Publishing)</i> , 2016 , 14, 184-193	1.1	2
13	Metabolic-Inflammation Aspects of Depression and Cardiovascular Disease 2016 , 211-233		
12	The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>International Journal of Neuropsychopharmacology</i> , 2015 , 19,	5.8	121
11	Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 132, 180-91	6.5	62
10	Therapeutic Angiogenesis by Ultrasound-Mediated MicroRNA-126-3p Delivery. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 2401-11	9.4	59

9	Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2015 , 188, 134-42	6.6	16
8	Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. <i>Journal of Affective Disorders</i> , 2015 , 188, 149-59	6.6	94
7	Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2015 , 13, 636-55	7.6	40
6	Inflamed moods: a review of the interactions between inflammation and mood disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 53, 23-34	5.5	363
5	Depression, Diabetes and Dementia. <i>Key Issues in Mental Health</i> , 2014 , 42-53		1
4	Major depressive disorder and type II diabetes mellitus: mechanisms underlying risk for Alzheimer's disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1740-9	2.6	10
3	Resolution of electroconvulsive therapy refractory major depressive disorder with unintentional hypoglycemic seizure: a case report. <i>Journal of ECT</i> , 2013 , 29, e47-8	2	
2	APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. <i>Journal of Controlled Release</i> , 2011 , 154, 298-305	11.7	65
1	Physical health and metabolic dysfunction in bipolar disorder 256-268		